Focus:
US-based clinical-stage biotechnology company Goldfinch Bio has entered an agreement with Japanese firm Takeda Pharmaceutical for global rights to a preclinical, peripherally restricted cannabinoid receptor 1 (CB1) monoclonal antibody.
GSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency virus (HIV) antiretroviral therapy (ART) on people living with the...
The UK’s Competition and Markets Authority (CMA) has alleged that South Africa-based pharmaceutical company Aspen has entered an illegal agreement with Amilco and Tiofarma for marketing Addison’s disease drug, fludrocortisone...
Gilead Sciences has secured the US Food and Drug Administration (FDA) approval for Descovy in pre-exposure prophylaxis (PrEP) to mitigate the risk of sexually acquired HIV-1 infection.
The UK’s National Institute for Health and Care Excellence (NICE) has rejected the first targeted immunotherapy treatment for people with triple negative breast cancer for use on the NHS.
Merck has announced that Keytruda has been approved by the Chinese National Medical Products Administration (NMPA) as a monotherapy for first-line treatment of local advanced or metastatic non-small cell lung...
French pharmaceutical company Servier has purchased Pixuvri medicine, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma.
Novartis has allied with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and commercialisation of medicines.
US pharma giant Johnson & Johnson (J&J) has announced the resolution and settlement of all opioid-based lawsuits with two Ohio counties, Cuyahoga and Summit, for $10m. This means the company...
Roche has announced positive results of Tecentriq (atezolizumab) combined with platinum-based chemotherapy in a Phase III study of patients with previously untreated advanced or metastatic urothelial carcinoma.
Go Top
